ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • Register
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 1968

A Drug Repurposing Story: New Therapeutic Tools Ready to Block Innate Immune Responses in Osteoarthritis

Eloi Franco-Trepat1, Ana Alonso-Pérez 1, Maria Guillán-Fresco 1, Alberto Jorge-Mora 2, Ana Lois Iglesias 3, Oreste Gualillo 4 and Rodolfo Gómez 1, 1Institute IDIS - Musculoskeletal Pathology Group, Santiago de Compostela, Spain, 2Institute IDIS - Musculoskeletal Pathology Group, Santiago de Compostela, 3Institute IDIS - Musculoskeletal Pathology Group, Santiago de Compostela, Galicia, Spain, 4Institute IDIS - NEIRID Lab - SERGAS, Santiago de Compostela, Spain

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: drug repurposing, IL6 and MMP9, Osteoarthritis, TLR4

  • Tweet
  • Email
  • Print
Save to PDF
Session Information

Date: Tuesday, November 12, 2019

Session Title: Osteoarthritis & Joint Biology – Basic Science Poster

Session Type: Poster Session (Tuesday)

Session Time: 9:00AM-11:00AM

Background/Purpose: Rheumatic diseases, also known as musculoskeletal pathologies, are steadily rising their prevalence. This worldwide phenomenon is depriving our society of their life quality and has become a grave economic burden. Among musculoskeletal pathologies, osteoarthritis (OA) stands as the major rheumatic disease, in fact, the World Health Organization (WHO) included OA within the TOP10 most disabling diseases.

The activation of Toll-like receptors (TLRs) by damage-associated molecular patterns (DAMPS) promotes critical innate immune responses (IIR). Although TLR4 and OA IIR are linked, no drugs are available to block TLR4 in rheumatology. Interestingly, TLR4 share downstream signaling with interleukin 1 receptor (IL1R). The development of new drugs is necessary but requires decades of work and billions in investment. An alternative exists, the search for anti-TLR4 properties in currently available drugs.

Amitriptyline (AT) is a tricyclic antidepressant currently in-use for neuropathies. Naloxone (NLX) swiftly reverse opioid overdose thanks to its antagonist design. Thalidomide (TALI) initially used as a sedative was found to be teratogenic. In the present, it is used as an anti-neoplastic and to combat leprosy.

Recent studies indicate that AT, NLX and TALI might have anti-TLR4 activity, and could be repurposed to the rheumatology field.

Methods: AT [1µM], NLX [100µM] and TALI [500µM] effect on IIR was initially studied in mouse chondrocytes (ATDC5) and human synoviocytes (SW982) to evaluate the drug effects in the whole joint. Next, it was validated in human OA chondrocytes (hOAC) isolated from knee-joint replacements. Gene expression was evaluated by RT-PCR. Protein levels were determined by ELISA and MALDI/TOFF. Cell viability was evaluated by MTT assay.

Results: At the studied concentrations, AT reduced cell culture nitrite accumulation (Griess assay) and did not affect cell viability (MTT assay). NLX and TALI also reduced cell culture nitrite accumulation (Griess assay).

Stimulation with TLR4 agonist LPS [100ng/ml] or IL1R agonist IL1B [0,5ng/ml] increased IIR gene expression (LCN2, IL6, MCP1, COX2, NOS2, MMP9, MMP13, and ADAMTS4) in chondrocytes (hOAC & ATDC5) and synoviocytes (SW982). Inhibition of TLR4 by CLI95 [3µM] reduced IIR gene expression in LPS and IL1B-treated chondrocytes.

Upon treatment with AT, NLX or TALI, the observed IIR processes (mRNA) were significantly inhibited in synoviocytes and chondrocytes (Figure 1). AT showed the highest anti-TLR4 effect (↓95%) and was selected to perform a proteomic profile (MALDI-TOF) in hOAC. AT treatment depleted IIR-related pathways, including IL6 (Figure 1). To further validate the proteomic results, IL6 protein secretion was evaluated (ELISA) and showed reduced levels after AT treatment.

Conclusion: We show in chondrocytes and synoviocytes:

  1. TLR4 receptor is involved in IL1β-mediated innate immune responses (IIR).
  2. Amitriptyline, thalidomide, and naloxone blocked TLR4 and IL1R –mediated IIR gene expression.
  3. Amitriptyline inhibited the expression of multiple TLR4 and IL1R –mediated IIR proteins.

The rheumatologists have a new therapeutic tool to manage innate immune responses in osteoarthritis.

Figure 1 – Effect of amitriptyline on TLR4-mediated and IL1R-mediated innate immune responses. OA human chondrocytes were stimulated with thalidomide -TALI- [500µM], naloxone -NLX- [100 µM] or amitriptyline -AT- [1µM], and TLR4 agonist LPS [100ng/ml] or the IL1R agonist IL1B [0,1ng/ml]. Pro-inflammatory factor interleukin-6 -IL6- was studied in human primary OA chondrocytes by RT-PCR and protein profiling MALDI/TOFF. A 4-way Venn diagram, differential Heatmap profile selection, a biological processes enrichment was done. Several cut-offs were carried out: 1st – false discovery rate -FDR- of 5% + p-value ±20% -Heatmap-, 3rd augmented relevant immune IIR biological processes -Pathway enrichment analysis-. Results are presented as mean ± SEM of four independent experiments. *p < 0.05; **p < 0.01; ***p < 0.001 versus stimulated control -LPS or IL1B-. Statistical significance was determined by One-Way ANOVA analysis followed by a Tukey Post-Test.


Disclosure: E. Franco-Trepat, None; A. Alonso-Pérez, None; M. Guillán-Fresco, None; A. Jorge-Mora, None; A. Lois Iglesias, None; O. Gualillo, None; R. Gómez, None.

To cite this abstract in AMA style:

Franco-Trepat E, Alonso-Pérez A, Guillán-Fresco M, Jorge-Mora A, Lois Iglesias A, Gualillo O, Gómez R. A Drug Repurposing Story: New Therapeutic Tools Ready to Block Innate Immune Responses in Osteoarthritis [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/a-drug-repurposing-story-new-therapeutic-tools-ready-to-block-innate-immune-responses-in-osteoarthritis/. Accessed January 20, 2021.
  • Tweet
  • Email
  • Print
Save to PDF

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/a-drug-repurposing-story-new-therapeutic-tools-ready-to-block-innate-immune-responses-in-osteoarthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Convergence: Where Rheumatology Meets. All Virtual. November 5-9.

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2021 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.